A New Piece of the Preeclampsia Puzzle

The field of obstetrics and gynecology has a lack of research for many reasons. Historically, women were excluded from medical trials and studies, so much of our knowledge today is based on a male body. Plus, the added risk and complexity around maternal/fetal studies makes researchers very cautious, which is very well founded in ethical concerns (Borahay et al., 2025). Nonetheless, it makes for very few studies about obstetrics. As someone who wants to become an OBGYN one day, I am always on the lookout for new information in the field, so when these research articles came across my email inbox, I knew they would be worth the read.

What is Preeclampsia?

Preeclampsia is a common condition during pregnancy. It is thought to be caused by increased vascular resistance, and results in the mother having high blood pressure. In normal development, the mother’s uterine artery is widened to allow enough blood to flow through the placenta to provide the baby with oxygen and nutrients. However in preeclampsia patients, the vessels do not widen like usual, and restrict blood flow. This restriction causes stress factors to be released into the blood stream, which causes blood vessels to narrow all over the body (Roland, 2024). This is what causes the high blood pressure, and often causes fetal growth restriction due to the baby not getting enough nutrients because of the restricted blood flow. Fortunately, preeclampsia can be treated and is common enough that it is routine to check for at appointments.

New Findings

The study that came across my inbox was from the journal Nature Medicine and shows that there may be a protein marker for preeclampsia, which can not only improve diagnostic methods, but give more insight to the cellular basis of the condition. As I’ve learned in my cellular and molecular biology class this semester, learning the cellular basis of conditions can help make massive strides towards improving treatments. It allows researchers to develop treatments that target the root cause instead of simply treating the symptoms of a condition.

Isthmin-2 (ISM2) is a protein almost exclusively produced in the placenta during the first trimester of pregnancy. A large clinical trial showed that patients with preeclampsia had much lower levels of ISM2 than those without. They then determined that ISM2 is necessary for extravillous trophoblasts (EVTs, a type of placental cell) to complete their functions of anchoring the placenta to the uterine wall and widen the maternal uterine artery (Miao et al., 2026).

This new information leads researchers to a possible conclusion that the issues causing preeclampsia could be caused by a deficiency in the ISM2 protein, since low levels can prevent the widening of the uterine artery, causing vascular resistance and increasing blood pressure (Nature Index, n.d.).

Translational Medicine

As I mentioned before, there are a lot of ethical concerns surrounding experiments in obstetrics, but advancements in organ models are making them more feasible. The placenta especially has been a larger topic recently for a few reasons. Human pregnancy is significantly distinct from the usual mammal models used in experiments. Mice are the most common, but their placentas do not implant as deep into the uterine wall as humans, so would not be a good model for this experiment. Instead, researchers have used stem cells to make organoid cultures, which can be used to get results that most accurately reflect the human body (Turco et al., 2018). These advancements are vital to a growing field called translational medicine, which bridges the gap between research done in labs and clinical medicine. As Michigan State’s Translational Neuroscience says, the ultimate goal of translational science is to translate science into better health. I know I am excited to see where else this knowledge can take us.

References

Borahay, M. A., Alperin, M., Turok, D., Coutifaris, C., Santoro, N., Burd, I., Barroilhet, L., Cedars, M. I., Rice, L. W., & Alvarez, R. D. (2025). Addressing the crisis in women’s health research: An American Gynecological and Obstetrical Society statement. American Journal of Obstetrics and Gynecology, 233(2), 79–81. https://doi.org/10.1016/j.ajog.2025.05.002

Roland, J. (2024, September 4). Preeclampsia vs. eclampsia: What’s the difference? Healthline. https://www.healthline.com/health/pregnancy/preeclampsia-vs-eclampsia

Miao, R., Gong, S., Sovio, U., Aye, I. L. M. H., Avellino, G., Guettler, J., Rogers, S. N., Cook, E., Toribio, A., Bergman, L., Lager, S., Wikström, A.-K., IMPACT Consortium, Kirk, P. D. W., Charnock-Jones, D. S., Smith, G. C. S., et al. (2026). Isthmin-2 is a first-trimester predictor of preeclampsia and fetal growth restriction. Nature Medicine, 32, 3351–3358. https://doi.org/10.1038/s41591-026-04573-6

Nature Index. (n.d.). Trophoblast cell invasion mechanisms in pregnancy. https://www.nature.com/nature-index/topics/l4/trophoblast-cell-invasion-mechanisms-in-pregnancy

Turco, M. Y., Gardner, L., Kay, R. G., Hamilton, R. S., Prater, M., Hollinshead, M. S., McWhinnie, A., Esposito, L., Fernando, R., Skelton, H., Reimann, F., Gribble, F. M., Sharkey, A., Marsh, S. G. E., O’Rahilly, S., Hemberger, M., Burton, G. J., & Moffett, A. (2018). Trophoblast organoids as a model for maternal-fetal interactions during human placentation. Nature, 564, 263–267. https://doi.org/10.1038/s41586-018-0753-3

Michigan State University. (n.d.). What is translational science? https://translationalscience.msu.edu/about/translational-science.html

Avatar photo
Savannah Spires

I am a biochemistry major at Georgia Tech and love nerding out about science! My favorite thing is when I can apply what I've learned in class to other topics. Right now, I've been loving using my organic chemistry knowledge to understand enzyme reactions and I can't wait to share that with you all!

Articles: 8